What Does HER2 Positive Mean for Treatment?

HER2 positive means the cancer makes too much of a protein called HER2, which pushes it to grow and spread faster. It used to be worrying news, but it now opens the door to targeted drugs like trastuzumab that lock onto HER2 and work alongside chemotherapy and surgery. So while these cancers are more aggressive by nature, they’re also among the most treatable today thanks to that targeted approach.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “Twenty years ago HER2 positive was bad news, today it’s almost the opposite, because we have drugs that target it directly, so I treat that result as an opportunity, not a setback.”

The result points to how the cancer behaves and, more importantly, how to fight it. Here’s what it signals.

• Extra HER2 protein: The cancer cells carry far too much of this growth signal, which is what drives them to multiply more quickly than usual.
• More aggressive type: Left untreated it tends to grow and spread faster, so it’s taken seriously and treated promptly once confirmed.
• A clear target: That same protein is its weak spot, since targeted drugs can lock onto HER2 in a way that spares healthy cells.
• Confirmed by testing: The status comes from lab testing on the tumour, and a borderline result is double-checked before treatment is set.

So the label tells you both the threat and the route to beat it. The status itself comes from an IHC test, which reads exactly this kind of marker on the tumour.

A positive result reshapes the plan in a good way, adding tools that wouldn’t otherwise apply. These are the main shifts.

• Targeted therapy added: Drugs like trastuzumab go straight after the HER2 protein, and they’ve transformed outcomes for these cancers.
• Chemo works with it: Targeted therapy usually pairs with chemotherapy, the two together hitting the cancer harder than either alone.
• Surgery still matters: Removing the tumour stays central, with the targeted drugs working before or after to clear what’s left.
• Closer monitoring: Because these cancers move faster, follow-up tends to be tighter to catch any change early.

So HER2 positive today means more weapons, not fewer. When surgery is part of that plan, robotic cancer surgery can remove the tumour precisely while recovery stays short.

Dr. Sandeep Nayak brings 24 years of surgical oncology experience, DNB qualifications in Surgical Oncology and General Surgery and a fellowship in Laparoscopic and Robotic Onco-Surgery to the treatment of HER2 positive and all other cancer types. He builds the surgery around the full molecular picture, so a marker like HER2 shapes the plan from the very start rather than later.

That joined-up approach is what gives targeted treatment its best footing. Every case at MACS Clinic goes through a full tumour board, where pathology, oncology and imaging weigh in together before anything is confirmed. Call +91 8104310753 to book your consultation.

References:

1. National Cancer Institute — HER2 and Cancer. https://www.cancer.gov/
2. World Health Organisation — Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer